| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.8M | 0.00% | 377.94K | −7.0% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 9, 2026 | Gottschalk AdrianChief Executive Officer | Stock Gift at price 0.00 per share. | 106.7K | — |
| Apr 24, 2025 | Gottschalk AdrianChief Executive Officer | Stock Gift at price 0.00 per share. | 300K | — |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Buy / hold / sell counts
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.7 | -0.5 | -15.8 | -0.6 | -9.9 | 14.0 | -7.2 | 26.7 | -37.8 | -48.2 | −65.7% | ||
| 2025 | -11.2 | 15.8 | -24.7 | 15.1 | -2.9 | 15.2 | 11.7 | -3.6 | -3.4 | -9.8 | 7.7 | 13.7 | +14.4% |
| 2024 | -50.7 | 143.1 | -13.2 | -18.6 | 6.8 | -1.4 | 22.1 | 17.9 | 12.4 | -18.2 | 4.9 | -40.9 | −26.8% |
| 2023 | 34.8 | -33.4 | 8.2 | 5.2 | -3.5 | 11.9 | 30.1 | -17.4 | -33.9 | -33.0 | 26.9 | 51.8 | +1.1% |
| 2022 | -32.8 | -37.5 | 58.5 | -23.9 | 11.3 | 5.4 | 7.6 | -32.1 | -13.7 | 1.9 | -22.8 | -5.5 | −72.1% |
| 2021 | -18.6 | -0.2 | -19.9 | -16.7 | -5.2 | 2.5 | -15.0 | 43.1 | 7.3 | -8.9 | -8.8 | 97.7 | +12.8% |
| 2020 | 26.4 | 0.3 | +26.8% |
No member of Congress has disclosed a FHTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades